Korean Pharma Calls For New Policy ‘Control Tower’, More Support
Executive Summary
Amid the recent ousting of President Park Geun-hye amid corruption allegations and a new presidential election only weeks away, the South Korean pharma industry is quickening its calls for policy support from the next administration by recommending a variety of changes.
You may also be interested in...
New Korean President Set To Maintain Pharma Policy Support
New South Korean President Moon Jae-in appears likely to continue to nurture the pharma and biotech industries by generally favorable policies such as improving the domestic drug pricing system to aid the global market entry of locally-originated novel drugs, and looks set to consider industry proposals for a new government R&D ‘control tower’.
Korea Needs ‘More Unified’ Bio-Health Care Policy: Experts
At a recent seminar in Seoul, South Korean biotechnology and health care experts positively assessed the government's ongoing efforts to nurture the sector, but called for more unified policies and clearer objectives going forward.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.